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a b s t r a c t
Post-translational modiﬁcations (PTMs) are chemical alterations to a protein following translation, regu-
lating stability and function. Reversible phosphorylation is an example of an important and well studiedeceived in revised form 6 July 2010
ccepted 21 July 2010
vailable online xxx
eywords:
PTM involved in a number of cellular processes. SUMOylation is another PTM known to modify a large
number of proteins and plays a role in various cellular processes including: cell cycle regulation, gene
transcription, differentiation and cellular localisation. Therefore, understanding the role of SUMOylation
in cell biology may allow the development of more efﬁcient models, important in streamlining the drugost-translational modiﬁcation
UMO
ell biology
discovery process. This review will focus on protein SUMOylation and its role in stem cell and somatic
cell biology.
© 2010 Elsevier Ireland Ltd. All rights reserved.
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. Post-translational modiﬁcations
Post-translational modiﬁcations (PTMs) involve the addition of
such as phosphorylation (Burnett and Kennedy, 1954), methyla-
tion (Grewal and Rice, 2004), acetylation (Glozak et al., 2005) and
glycosylation (Spiro, 2002); regulating various biological activitiesPlease cite this article in press as: Hannoun, Z., et al., Post-translational mod
chemical group following protein translation (Walsh et al., 2005).
TMs are essential for a variety of cellular processes and provide
nother level of protein regulation, which is usually reversible.
here are a large number of PTMs that take place in the cell
∗ Corresponding author. Tel.: +44 131242 6164.
E-mail address: davehay@talktalk.net (D.C. Hay).
300-483X/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.tox.2010.07.013such as transcriptional regulation (Waby et al., 2008) and protein
degradation (Orford et al., 1997).iﬁcation by SUMO. Toxicology (2010), doi:10.1016/j.tox.2010.07.013
2. SUMO—small ubiquitin like modiﬁers
SUMOylation, another type of PTM, has a diverse range of effects
within the living cell (Johnson, 2004). SUMO proteins are highly
conserved in a large number of species and have been shown to be
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Fig. 1. The SUMO conjugation and deconjugation pathway. The SUMO conjugation pathway requires the activity of four enzymes: SENP the SUMO speciﬁc protease family;
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a1 composed of 2 subunits Uba2/Aos1; E2—Ubc9 and the E3 ligases. The reaction i
UMO speciﬁc proteases (SENPs). Following which, the E1 enzyme, a heterodimer
onjugating enzyme Ubc9. Ubc9 forms a reactive bond between itself and SUMO. S
n isopeptide bond, to the target protein. This process is in equilibrium with the SU
mportant in many eukaryotic cell processes (Hayashi et al., 2002)
ncluding: cell cycle regulation, transcription, cellular localisation,
egradation and chromatin organisation (Müller et al., 2001; Seeler
ndDejean, 2003;Verger et al., 2003).Despite thename, SUMOonly
hares ∼18% homology with ubiquitin (Müller et al., 2001) and is
pproximately 11kDa in size, comparable to the 8kDa ubiquitin
olecule (Müller et al., 2001). SUMO has been found to bind to the
ysine residueon the followingconsensus sequence;KxE (where
orresponds to a largehydrophobic aminoacid, K is a lysine residue,
is any amino acid and E is a glutamic acid residue) on the target
rotein. Three homologues exist in mammals, SUMO-1, -2 and -
. SUMO-2 and -3 share 95% homology with each other, but only
hare 50% identity with SUMO-1 (Johnson, 2004). SUMO-2 and -
have the ability to form polySUMO chains, covalently binding
o themselves via the lysine residue at the N terminus consensus
otifKxE. SUMO-1 lacks this consensus site and as a consequence
s unable to form polychains (Kroetz, 2005) and acts as a polySUMO
hain terminator (Ulrich, 2009).
. SUMO conjugation
.1. Pathway overview
The SUMO conjugation pathway has a lot in common with the
biquitination pathway. Both processes involve the use of three
nzymes: E1: activating enzyme, E2: conjugating enzyme and E3:
igase (Fig. 1) (Takahashi et al., 2001). SUMO is bound to its tar-
et protein via an isopeptide bond formed between an -amino
roup on the lysine residue on the target protein and the C ter-
inal carboxyl group on the SUMO protein (Desterro et al., 1997).
he pro-form of SUMO needs to be cleaved prior to protein con-
ugation. This is carried out by isopeptidases, also known as the
ENP SUMO deconjugating enzymes (Mukhopadhyay and Dasso,
007). The SUMO activating enzyme (E1), SAE1/2, commences the
eaction process by interacting with SUMO (activated by SENPPlease cite this article in press as: Hannoun, Z., et al., Post-translational mod
nzymes—Fig. 1), to form a high energy thiolester bond. The SUMO
onjugating enzyme (E2) then binds SUMO via its cysteine residue
n its active site. This intermediate provides a highly reactive
pecies, important in the ﬁnal conjugation, usually facilitated by
n E3 ligase (Kroetz, 2005). SUMO E3 ligases act to either activateated by cleaving the pro-form of SUMO at its C terminus, to its active state, by the
a2/Aos1, binds SUMO in an ATP dependant reaction, before the transfer to the E2
uently, the E3 ligase facilitates the transfer and covalent attachment of SUMO, via
econjugation (SENPs) machinery which cleaves the isopeptide bond.
Ubc9 or bring Ubc9 and the target proteinwithin close proximity of
each other, thus enhancing SUMOylation (Ulrich, 2009). They can
be regarded as E3 enzymes as they are able to bind to the E2 and the
substrate and facilitate the formation of the bond formed between
SUMO and the target protein. It has also been shown that a large
number of proteins (∼40%) can be SUMOylated without the pres-
ence of the consensus sequence (KxE), demonstrating differences
in substrate speciﬁcity (Ulrich, 2009).
3.2. The enzymes involved
3.2.1. E1
Unlike the ubiquitin (Ub) E1, the SUMO E1 exists as a het-
erodimer;with eachmonomer corresponding to a particular region
of the Ub E1. The SAE subunit Aos1 (SAE1) shares similarity with
the N terminus of the Ub E1, whilst Uba2 (SAE2), the second com-
ponent of the SAE complex, is similar to the C terminus of the Ub E1
(Johnson et al., 1997). The monomers are never found individually
and hence it is assumed that they are unable to function indepen-
dently (Azuma et al., 2001). The SAE complex is responsible for
preparing SUMO for transfer to the SUMO conjugating enzyme,
Ubc9 (Walden et al., 2003).
3.2.2. E2
Ubc9 is the only known SUMO conjugating enzyme, unlike the
ubiquitination pathway where each E2 has a speciﬁc set of tar-
get proteins (Hayashi et al., 2002). Ubc9 contains an active site
with a cysteine residue which is responsible for binding the SUMO
molecule directly to theKxE sequence found on the target protein
(Sternsdorf et al., 1999).
3.2.3. E3
In contrast to SUMO E2s, a larger number of SUMO E3 lig-
ases have been discovered and have been categorized into three
types: the protein inhibitor of activated STAT—signal transduceriﬁcation by SUMO. Toxicology (2010), doi:10.1016/j.tox.2010.07.013
and activator of transcription (PIAS) family (Hochstrasser, 2001),
the nuclear pore proteins Ran binding protein 2 and nucleoporin
358 (RanBP2/Nup358) (Pichler et al., 2002) and thepolycombgroup
protein Pc2 (Kagey et al., 2003). E3 ligases are usually substrate
speciﬁc with little redundancy found within the system.
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Fig. 2. In vitro SUMOylation of RanGAP. An in vitro SUMOconjugation assaywas car-
ried out to SUMOylate the RanGAP protein. RanGAP was incubated with the SUMO
conjugation machinery; SUMO1, SAE1/2 and Ubc9 under the following conditions:
10l containing 50mM Tris pH 7.5, 5mM MgCl2, 2mM ATP, 5mM DTT, 100ng
SAE2/1 (E1), 100–600ng UBc9 (E2), Sumo 2.5g and substrate 1–3g. The solution
was incubated at 37 ◦C for 2.5h and the reaction was stopped by the addition of
LDS sample buffer. An additional control was added where the SUMO conjugated
RanGAP is deconjugated using SENP 1. The conditions for the reaction are as fol-
lows: iodoacetamide was added to the conjugated RanGAP solution at 10mM and
incubated at room temperature for 30min.-Mercaptoethanol or DTT was added at
20mM and left for 15min at room temperature. SENP1 was ﬁnally added at 10nM
and incubated for 1h at 37 ◦C. The reaction was stopped by the addition of LDS
buffer. The samples were run on an SDS-PAGE gel and were then used to detect
SUMO conjugation using Western blotting. The membranes were ﬁrst probed for
RanGAP (1:500) and as seen in this ﬁgure, an upper band is observed, a 10kDa shift
upwards; where free RanGAP is approximately 32kDa and SUMOylated Ran GAP
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4s approximately 42kDa. In the control lane with the addition of SENP1, the upper
and disappears; suggesting RanGAP is SUMO modiﬁed in vitro. The same mem-
rane was stripped and probed for SUMO 1 (1:1000), as shown in this ﬁgure; the
pper band is also SUMO positive.
The largest group of E3 ligases are the PIAS proteins with four
enes in mammals: PIAS1, PIAS3, PIASx and PIAS (Liu et al., 1998).
he PIAS E3s have a conserved region consisting of a SAP domain
esponsible for binding AT rich DNA sequences and an SP-RING
omain which binds to Ubc9 and promotes SUMOylation (Schmidt
nd Müller, 2002). They also contain SUMO interaction motifs
SIMs) that are able to directly bind SUMO (Rytinki et al., 2009). It
as been found that the different PIAS proteins SUMOylate distinct
ets of substrates, with occasional overlap (Schmidt and Müller,
002). The second group of E3 SUMO ligases consists of the nuclear
ore protein RanBP2 (Nup358) with only one known substrate,
anGAP1, a GTPase activating protein important in nuclear trans-
ort of proteins (Nishimoto, 1999; Saitoh et al., 1997).Wehave also
hown that RanGAP can be SUMO modiﬁed in vitro, as displayed in
ig. 2. The ﬁnal family SUMO E3 ligase identiﬁed so far is the PC2
rotein part of the polycomb group (Kagey et al., 2003). Pc2 has
een shown to SUMOylate the transcriptional co-repressor CtBP,
ocalising it to the nucleus (Lin et al., 2003), and to co-localise with
cG bodies (Kagey et al., 2003).
.3. Regulation of SUMO modiﬁcation
SUMO modiﬁcation is a dynamic process involving both con-
ugation and deconjugation enzymes. The deconjugation enzymes
unction by cleaving the isopeptide bond between SUMO and the
odiﬁed protein (Melchior et al., 2003). There are seven isoforms
f these isopeptidases, including SENP1, SENP2, SENP3, SENP6 and
ENP7 (Mukhopadhyay and Dasso, 2007). The SENPs contain a Ulp
omain at their C terminus responsible for cleaving the isopeptide
ond and distinct N terminal domains that regulate their cellular
ocalisation, suggesting each SENP has a distinct set of substrates
Mukhopadhyay and Dasso, 2007). In addition to their deconjuga-Please cite this article in press as: Hannoun, Z., et al., Post-translational mod
ion role, the SENPs also play an essential role in maintaining the
evels of free SUMO within the cell (Ulrich, 2009). Other forms of
UMOregulation include theE3 ligases and thepresenceof the con-
ensus motif on target proteins. It has previously been stated that
0% of proteins modiﬁed by SUMO do not have the typical consen- PRESS
y xxx (2010) xxx–xxx 3
sus sequence; as such this could also be regarded as another form
of regulation.
4. The role of SUMO conjugation in the cell
Over the last decade a number of groups have investigated how
the SUMO pathway is regulated in response to different stimuli.
In response to heat shock, erythroleukemia cells induce transcrip-
tion of heat shock factor 1 (HSF1). After its translation, HSF1 is
phosphorylated prior to its SUMOylation, which enhances its DNA
binding ability (Hong et al., 2001). It is also widely recognised that
SUMO alters protein activity by modulating other PTMs, such as
phosphorylation and ubiquitination. For example, SUMOylation of
IB, an important factor in the inﬂammatory response, prevents
its ubiquitination, and therefore inhibits its degradation and subse-
quent NF-B activation and nuclear translocation (Desterro et al.,
1998). SUMO can also regulate protein activity by modulating its
interactions with other macromolecules or proteins. Various mod-
els have been proposed such as the addition of SUMO by altering
protein conﬁguration, creating a new interaction motif affecting
its function (Johnson, 2004). An interesting example of interaction
motifs is arsenic induced RNF4 mediated degradation of promye-
locytic leukemia (PML) bodies. In the presence of arsenic, PML is
polySUMOylated, and following the recruitment of RNF4, an E3 Ub
ligase, PML is ubiquitinated and degraded (Tatham et al., 2008).
5. SUMO modiﬁcation plays an important role in
development and cell biology
Various studies have shown that disruption of the SUMO path-
way causes abnormal cellular differentiation. Moreover, disruption
of the SUMO pathway during embryogenesis may lead to embryo
lethality (Nacerddine et al., 2005; Nowak and Hammerschmidt,
2006), demonstrating the requirement for SUMOylation during
development. Due to the lethal nature of Ubc9 knock outs during
development, other experimental strategies are necessary to deter-
mine theprecise roleof SUMOylation. In vitro, therehasbeena focus
on the role of SUMOylation in anumberof cell types, humanembry-
onic stem cells (hESCs) and representatives of all three germ layers.
These models, although not in vivo, provide a good developmental
surrogate.
5.1. Human embryonic stem cells
Humanembryonic stemcells (hESCs) are isolated from the inner
cell mass of blastocyst stage embryos and are self-renewing cells
capable of forming cell types from the three germ layers: meso-
derm, endoderm and ectoderm (Fletcher et al., 2008). The ability
to culture hESCs under standardized conditions and differentiate
these cells into a variety of cell types using highly efﬁcient and
reproducible protocols may provide an inexhaustible resource for
clinical and industrial application (Hannoun et al., 2010a,b; Hay et
al., 2008). SUMO modiﬁcation has been shown to have an impor-
tant role in both hESC self-renewal and pluripotency (Wei et al.,
2007). Oct4 is a POU transcription factor associated with the undif-
ferentiated and pluripotent status of embryonic stem cells (Hay et
al., 2004; Hardeland et al., 2002; Nichols et al., 1998). It is known
to be SUMO modiﬁed, which results in its increased stability, DNA
binding and transcriptional activity (Wei et al., 2007) (Fig. 3). Sex
determining region Y box 2 (SOX2) is another important transcrip-iﬁcation by SUMO. Toxicology (2010), doi:10.1016/j.tox.2010.07.013
tion factor required for embryonic stem cell self-renewal in an
undifferentiated state (Cai et al., 2006). It was recently shown by
Hoof andcolleagues that SOX2 is SUMOmodiﬁedasa result of phos-
phorylation. It has been suggested that SUMOmodiﬁcation of SOX2
affects its transcriptional activity (Hoof et al., 2009; Hietakangas et
ARTICLE IN PRESSGModelTOX-50617; No.of Pages6
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Fig. 3. The effect of SUMO modiﬁcation in various cell types. SUMO modiﬁcation affects a number of cellular processes. (A) In human embryonic stem cells (hESCs), SUMO
binds to Oct4 in the nucleus (blue), enhancing its stability and transcriptional activity which is an important regulatory mechanism in hESC self-renewal and pluripotenty.
SUMO modiﬁcation also plays an important role in somatic cell biology. (B) In cardiomyocytes, SUMOylation regulates the properties of the Kv1.5 potassium voltage channel
located at the plasma membrane. These channels play an essential role in cardiomyocyte membrane potential. The inhibition of SUMO modiﬁcation to the Kv1.5 channel
results in the opening of membrane channels, exporting potassium ions, which results in cellular hyperpolarisation. (C) SUMO conjugation in hepatocytes regulates the
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iranscriptional activity of C/EBP impacting on albumin (ALB) expression within the
RG1/SW1/SNF essential for high level albumin expression. SW1/SNF is a chromatin
een shown to regulate the activity of the GluR6 receptor in neural cells by endocy
n SUMO modiﬁcation of GluR6, thus affecting neurone excitability.
l., 2006) but further investigation is required. The role of SUMOy-
ation has also been determined in cell types representative of the
hree germ layers: endoderm, mesoderm and ectoderm.
.2. Endoderm
The endoderm layer is formed during embryogenesis and is
he precursor of liver, pancreas and lung amongst others (Tam
t al., 2003). SUMOylation plays an important role in hepatocyte
iology regulating C/EBP, a crucial factor in hepatic differenti-Please cite this article in press as: Hannoun, Z., et al., Post-translational mod
tion (Pedersen et al., 2001; Sato et al., 2006). SUMOylation of
/EBP prevents its association with BRG1, a core subunit in the
W1/SNF chromatin remodelling unit, leading to the inhibition of
lbumin expression (Sato et al., 2006) (Fig. 3). In line with this,
t has been shown that there is a decrease in levels of SUMOyla-eus (blue). SUMO modiﬁcation of C/EBP inhibits its ability to form a complex with
delling complex and BRG is a core subunit of the complex. (D) SUMOylation has also
inate induced receptor internalisation on the cell plasma membrane is dependent
tion as rat hepatocytes mature (Sato et al., 2006), suggesting an
inhibitory effect of SUMOylation in hepatocyte terminal differenti-
ation. Themitochondria are anessential componentof hepatocytes,
the main cell type in the liver, and are required for efﬁcient liver
function. Mitochondrial levels in the cell are dynamic and contin-
uously undergo fusion and ﬁssion (Twig et al., 2008; Frazier et al.,
2006). It has been shown that an increase in SUMO-1 expression
results in an increase in mitochondrial fragmentation by stabilis-
ing the GTPase dynamin-related protein 1 (DRP1) (Harder et al.,
2004). Further investigation of this pathwayhas revealed that SENPiﬁcation by SUMO. Toxicology (2010), doi:10.1016/j.tox.2010.07.013
5, a SUMOdeconjugating enzyme, is required for normalmitochon-
drial morphology and levels of reactive oxidative species within
the cell, partly by SUMO deconjugation of DRP1 (Zunino et al.,
2007). In the pancreas, SUMO modiﬁcation of islet cell autoanti-
gen 512 (ICA512) has been shown to disrupt its binding to STAT5
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nd inhibit insulin and granule related gene transcription (Mziaut
t al., 2006).
.3. Mesoderm
During development the mesoderm differentiates into muscle,
artilage, bone, blood and connective tissue (Biggers and Borland,
976). The heart signiﬁcantly relies on the coordination of various
on channels for regular function. One such voltage gated channel is
he potassium channel Kv1.5 found in atrial myocytes which mod-
late membrane potential of smooth muscle cells (Lagrutta et al.,
006). Benson and colleagues have shown that Kv1.5 has two con-
erved consensus SUMOylation motifs, which play an important
ole in hyperpolarisation (efﬂux of potassium ions) (Benson et al.,
007) (Fig. 3). At the initial stages of development, the polycomb
protein (Pc2), part of the polycomb repressor complex 1(PRC1),
s SUMOylated. This allows efﬁcient complex formation and its
ecruitment to methylated histone 3 for controlled gene silencing.
n mesoderm formation, SENP2 is recruited to PRC1, deSUMOy-
ates the Pc2 protein and allows the expression of GATA4 and 6
ranscription factors essential for normal cardiac formation (Kang
t al., 2010). Interestingly, in adult cardiomyocytes, SUMO modi-
cation of GATA4 results in increased transcriptional activity, and
romotes cardiogenic gene activity (Wang et al., 2004).
.4. Ectoderm
Ectodermal differentiation results in the formation of the skin
nd nervous system (Pelton et al., 1998). SUMOylation also has a
ital role in the nervous system. GluR6 is a highly expressed kinate
eceptor found in thebrain, and is concentrated in thehippocampus
Nasu-Nishimura et al., 2010). The receptor is known to regulate
euronal excitability and as such is involved in learning, memory
nd synaptic plasticity (Barberis et al., 2008). It has been shown
hat the internalisation of the receptor upon kinate stimulation is
egulated by SUMOylation (Fig. 3). GluR6 is internalised via kinate
rN-methyl-d-aspartate (NMDA) induced endocytosis. Only kinate
nduced internalisation requiresGluR6 SUMOylation. Themutation
f the SUMO consensus motif in GluR6 results in a large reduc-
ion in kinate induced GluR6 internalisation and disrupts regular
ynaptic function (Martin et al., 2007). Another factor important
or both brain development and neuronal differentiation is MEF2A.
EF2A and its associated family members have been shown to be
nvolved in the proliferation, differentiation and apoptosis of cells
ound in the developing brain (McKinsey et al., 2002). SUMOylation
f MEF2A decreases its transcriptional activity, suppressing Nur77
unction; andpromotes dendritic clawdifferentiation (Shalizi et al.,
006).
. Conclusion
SUMOylation is an important PTM known to play roles embry-
nic stem cell and somatic cell biology. Given its importance in cell
iology, it is critical that we understand SUMOylation in order to
enerate stable and high ﬁdelity models that predict human drug
oxicity. These models will not only be useful tools for toxicol-
gy, but will also provide a system whereby we can investigate
he role(s) of SUMO modiﬁcation in response to numerous stimuli.
hiswill undoubtedly provide information onnovelmechanismsofPlease cite this article in press as: Hannoun, Z., et al., Post-translational mod
ctionwith thepossibility of developingnewmedicines andclinical
ntervention strategies.
onﬂict of interest statement
The authors report no conﬂict of interest. PRESS
y xxx (2010) xxx–xxx 5
Acknowledgements
Ms. Zara Hannoun was supported by a MRC Ph.D. studentship.
Dr. David Hay was supported by a RCUK fellowship. Mr. Sebastian
Greenhough was supported by an award from Genomia and Roslin
Cellab. Dr. Ronald Hay and Ellis Jaffray were supported by the CR-
UK.
References
Azuma, Y., Tan, S.H., Cavenagh, M.M., Ainsztein, A.M., Saitoh, H., Dasso, M., 2001.
Expression and regulation of the mammalian SUMO-1 E1 enzyme. FASEB J. 15,
1825–1827.
Barberis, A., Sachidhanandam, S.,Mulle, C., 2008.GluR6/KA2kainate receptorsmedi-
ate slow-deactivating currents. J. Neurosci. 28, 6402–6406.
Benson, M.D., Li, Q.J., Kieckhafer, K., Dudek, D., Whorton, M.R., Sunahara, R.K.,
In˜iguez-Lluhí, J.A., Martens, J.R., 2007. SUMO modiﬁcation regulates inactiva-
tion of the voltage-gated potassium channel Kv1.5. Proc. Natl. Acad. Sci. U.S.A.
104, 1805–1810.
Biggers, J.D., Borland, R.M., 1976. Physiological aspects of growth and development
of the preimplantation mammalian embryo. Annu. Rev. Physiol. 38, 95–119.
Burnett, G., Kennedy, E.P., 1954. The enzymatic phosphorylation of proteins. J. Biol.
Chem. 211, 969–980.
Cai, J., Chen, J., Liu, Y., Miura, T., Luo, Y., Loring, J.F., Freed, W.J., Rao, M.S., Zeng, X.,
2006. Assessing self renewal and differentiation in hESC Lines. Stem Cells 24 (3),
516–530.
Desterro, J.M., Rodriguez, M.S., Hay, R.T., 1998. SUMO-1 modiﬁcation of IkappaBal-
pha inhibits NF-kappaB activation. Mol. Cell. 2, 233–239.
Desterro, J.M., Thomson, J., Hay, R.T., 1997. Ubch9 conjugates SUMO but not ubiqui-
tin. FEBS Lett. 417, 297–300.
Fletcher, J., Cui,W., Samuel, K., Black, J.R., Hannoun, Z., Currie, I.S., Terrace, J.D., Payne,
C., Filippi, C., Newsome, P., Forbes, S.J., Ross, J.A., Iredale, J.P., Hay, D.C., 2008.
The inhibitory role of stromal cell mesenchyme on human embryonic stem cell
hepatocyte differentiation is overcome by Wnt3a treatment. Cloning Stem Cells
10, 331–339.
Frazier,A.E., Kiu, C., Stojanovski,D.,Hoogenraad,N.J., Ryan,M.T., 2006.Mitochondrial
morphology and distribution in mammalian cells. Biol. Chem. 387, 1551–1558.
Glozak, M.A., Sengupta, N., Zhang, X., Seto, E., 2005. Acetylation and deacetylation
of non-histone proteins. Gene 363, 15–23.
Grewal, S.I.S., Rice, J.C., 2004. Regulation of heterochromatin by histone methylation
and small RNAs. Curr. Opin. Cell Biol. 16, 230–238.
Hannoun, Z., Filippi, C., Sullivan, G., Hay, D.C., Iredale, J.P., 2010a. Hepatic endoderm
differentiation from human embryonic stem cells. Curr. Stem Cell Res. Ther..
Hannoun, Z., Fletcher, J., Greenhough, S.,Medine, C., Samuel, K., Sharma, R., Pryde, A.,
Black, J., Ross, J., Wilmut, I., Iredale, J., Hay, D., 2010b. The comparison between
conditionedmedia and serum-freemedia in human embryonic stem cell culture
and differentiation. Cell. Reprog. 12, 133–140.
Harder, Z., Zunino, R.,McBride,H., 2004. Sumo1conjugatesmitochondrial substrates
and participates in mitochondrial ﬁssion. Curr. Biol. 14, 340–345.
Hardeland, U., Steinacher, R., Jiricny, J., Schär, P., 2002. Modiﬁcation of the
human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzy-
matic turnover. EMBO J. 21, 1456–1464.
Hay, D.C., Fletcher, J., Payne, C., Terrace, J.D., Gallagher, R.C.J., Snoeys, J., Black, J.R.,
Wojtacha, D., Samuel, K., Hannoun, Z., Pryde, A., Filippi, C., Currie, I.S., Forbes,
S.J., Ross, J.A., Newsome, P.N., Iredale, J.P., 2008. Highly efﬁcient differentiation
of hESCs to functional hepatic endoderm requires ActivinA andWnt3a signaling.
Proc. Natl. Acad. Sci. U.S.A. 105, 12301–12306.
Hay, D.C., Sutherland, L., Clark, J., Burdon, T., 2004. Oct-4 knockdown induces similar
patterns of endoderm and trophoblast differentiation markers in human and
mouse embryonic stem cells. Stem Cells 22, 225–235.
Hayashi, T., Seki,M.,Maeda, D.,Wang,W., Kawabe, Y.I., Seki, T., Saitoh, H., Fukagawa,
T., Yagi, H., Enomoto, T., 2002. Ubc9 is essential for viability of higher eukaryotic
cells. Exp. Cell Res. 280, 212–221.
Hietakangas, V., Anckar, J., Blomster, H.A., Fujimoto, M., Palvimo, J.J., Nakai, A., Sisto-
nen, L., 2006. PDSM, amotif forphosphorylation-dependent SUMOmodiﬁcation.
Proc. Natl. Acad. Sci. U.S.A. 103, 45–50.
Hochstrasser,M., 2001. SP-RING for SUMO: new functions bloom for a ubiquitin-like
protein. Cell 107, 5–8.
Hong, Y., Rogers, R., Matunis, M.J., Mayhew, C.N., Goodson, M.L., Park-Sarge, O.K.,
Sarge, K.D., Goodson, M., 2001. Regulation of heat shock transcription fac-
tor 1 by stress-induced SUMO-1 modiﬁcation. J. Biol. Chem. 276, 40263–
40267.
Hoof, D.V., Javier, M., Stefan, R.B., Pinkse, M.W.H., Linding, R., Heck, A.J.R., Mummery,
C.L., Krijgsveld, J., 2009. Phosphorylation dynamics during early differentiation
of human embryonic stem cells. Cell Stem Cell 5, 214–226.
Johnson, E.S., Schwienhorst, I., Dohmen, R.J., Blobel, G., 1997. The ubiquitin-like pro-
tein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2piﬁcation by SUMO. Toxicology (2010), doi:10.1016/j.tox.2010.07.013
heterodimer. EMBO J. 16, 5509–5519.
Johnson, E.S., 2004. ProteinmodiﬁcationbySUMO.Annu.Rev. Biochem.73, 355–382.
Kagey, M.H., Melhuish, T.A., Wotton, D., 2003. The polycomb protein Pc2 is a SUMO
E3. Cell 113, 127–137.
Kang, X., Qi, Y., Zuo, Y., Wang, Q., Zou, Y., Schwartz, R.J., Cheng, J., Yeh, E.T.H.,
2010. SUMO-speciﬁc protease 2 is essential for suppression of polycomb group
 INGT
6 icolog
K
L
L
L
M
M
M
M
M
M
N
N
N
N
N
O
P
P
PARTICLEModelOX-50617; No.of Pages6
Z. Hannoun et al. / Tox
protein-mediated gene silencing during embryonic development. Mol. Cell 38
(2), 191–201.
roetz, M.B., 2005. SUMO: a ubiquitin-like protein modiﬁer. Yale J. Biol. Med. 78,
197–201.
agrutta, A., Wang, J., Fermini, B., Salata, J.J., 2006. Novel, potent inhibitors of human
Kv1.5 K+ channels and ultrarapidly activating delayed rectiﬁer potassium cur-
rent. J. Pharm. Exp. Ther. 317 (3), 1054–1063.
in, X., Sun, B., Liang,M., Liang, Y.Y., Gast, A., Hildebrand, J., Brunicardi, F.C.,Melchior,
F., Feng, X.H., 2003. Opposed regulation of corepressor CtBP by SUMOylation and
PDZ binding. Mol. Cell 11, 1389–1396.
iu, B., Liao, J., Rao, X., Kushner, S.A., Chung, C.D., Chang, D.D., Shuai, K., 1998. Inhibi-
tion of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. U.S.A. 95,
10626–10631.
artin, S., Nishimune, A., Mellor, J.R., Henley, J.M., 2007. SUMOylation regulates
kainate-receptor-mediated synaptic transmission. Nature 447, 321–325.
cKinsey, T.A., Zhang, C.L., Olson, E.N., 2002. MEF2: a calcium-dependent regulator
of cell division, differentiation and death. Trends Biochem. Sci. 27, 40–47.
elchior, F., Schergaut, M., Pichler, A., 2003. SUMO: ligases, isopeptidases and
nuclear pores. Trends Biochem. Sci. 28, 612–618.
ukhopadhyay, D., Dasso, M., 2007. Modiﬁcation in reverse: the SUMO proteases.
Trends Biochem. Sci. 32, 286–295.
üller, S., Hoege, C., Pyrowolakis, G., Jentsch, S., 2001. SUMO, ubiquitin’smysterious
cousin. Nat. Rev. Mol. Cell Biol. 2, 202–210.
ziaut, H., Trajkovski, M., Kersting, S., Ehninger, A., Altkrüger, A., Lemaitre, R.P.,
Schmidt, D., Saeger, H.D., Lee, M.S., Drechsel, D.N., Müller, S., Solimena, M., 2006.
Synergy of glucose and growth hormone signalling in islet cells through ICA512
and STAT5. Nat. Cell Biol. 8, 435–445.
acerddine, K., Lehembre, F., Bhaumik, M., Artus, J., Cohen-Tannoudji, M., Babinet,
C., Pandolﬁ, P.P., Dejean, A., 2005. The SUMO pathway is essential for nuclear
integrity and chromosome segregation in mice. Dev. Cell 9, 769–779.
asu-Nishimura, Y., Jaffe, H., Isaac, J.T.R., Roche, K.W., 2010. Differential regulation
of kainate receptor trafﬁcking by phosphorylation of distinct sites on GluR6. J.
Biol. Chem. 285, 2847–2856.
ichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I.,
Schöler, H., Smith, A., 1998. Formation of pluripotent stem cells in the mam-
malian embryo depends on the POU transcription factor Oct4. Cell 95, 379–391.
ishimoto, T., 1999. A new role of ran GTPase. Biochem. Biophys. Res. Commun. 262,
571–574.
owak, M., Hammerschmidt, M., 2006. Ubc9 regulates mitosis and cell survival
during zebraﬁsh development. Mol. Biol. Cell 17, 5324–5336.
rford, K., Crockett, C., Jensen, J.P., Weissman, A.M., Byers, S.W., 1997. Serine
phosphorylation-regulated ubiquitination and degradation of beta-catenin. J.
Biol. Chem. 272, 24735–24738.
edersen, T.A., Kowenz-Leutz, E., Leutz, A., Nerlov, C., 2001. Cooperation between
C/EBPalpha TBP/TFIIB and SWI/SNF recruiting domains is required for adipocytePlease cite this article in press as: Hannoun, Z., et al., Post-translational mod
differentiation. Genes Dev. 15, 3208–3216.
elton, T.A., Bettess, M.D., Lake, J., Rathjen, J., Rathjen, P.D., 1998. Developmental
complexity of earlymammalian pluripotent cell populations in vivo and in vitro.
Reprod. Fertil. Dev. 10, 535–549.
ichler, A., Gast, A., Seeler, J.S., Dejean, A.,Melchior, F., 2002. The nucleoporin RanBP2
has SUMO1 E3 ligase activity. Cell 108, 109–120. PRESS
y xxx (2010) xxx–xxx
Rytinki, M.M., Kaikkonen, S., Pehkonen, P., Jääskeläinen, T., Palvimo, J.J., 2009. PIAS
proteins: pleiotropic interactors associated with SUMO. Cell Mol. Life Sci. 66,
3029–3041.
Saitoh, H., Pu, R., Cavenagh, M., Dasso, M., 1997. RanBP2 associates with Ubc9p and
a modiﬁed form of RanGAP1. Proc. Natl. Acad. Sci. U.S.A. 94, 3736–3741.
Sato, Y., Miyake, K., Kaneoka, H., Iijima, S., 2006. Sumoylation of CCAAT/enhancer-
binding protein alpha and its functional roles in hepatocyte differentiation. J.
Biol. Chem. 281, 21629–21639.
Schmidt, D., Müller, S., 2002. Members of the PIAS family act as SUMO ligases
for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. U.S.A. 99,
2872–2877.
Seeler, J.S., Dejean, A., 2003. Nuclear and unclear functions of SUMO. Nat. Rev. Mol.
Cell Biol. 4, 690–699.
Shalizi, A., Gaudillière, B., Yuan, Z., Stegmüller, J., Shirogane, T., Ge, Q., Tan, Y., Schul-
man, B., Harper, J.W., Bonni, A., 2006. A calcium-regulated MEF2 sumoylation
switch controls postsynaptic differentiation. Science 311, 1012–1017.
Spiro, R.G., 2002. Protein glycosylation: nature, distribution, enzymatic formation,
and disease implications of glycopeptide bonds. Glycobiology 12, 43–56.
Sternsdorf, T., Jensen, K., Reich, B., Will, H., 1999. The nuclear dot protein sp100,
characterization of domains necessary for dimerization, subcellular localiza-
tion, and modiﬁcation by small ubiquitin-like modiﬁers. J. Biol. Chem. 274,
12555–12566.
Takahashi, Y., Toh-e, A., Kikuchi, Y., 2001. A novel factor required for the
SUMO1/Smt3 conjugation of yeast septins. Gene 275, 223–231.
Tam, P.P.L., Kanai-Azuma, M., Kanai, Y., 2003. Early endoderm development in ver-
tebrates: lineage differentiation and morphogenetic function. Curr. Opin. Genet.
Dev. 13, 393–400.
Tatham, M.H., Geoffroy, M.C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E.G.,
Palvimo, J.J., Hay, R.T., 2008. RNF4 is a poly-SUMO-speciﬁc E3 ubiquitin ligase
required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538–546.
Twig, G., Hyde, B., Shirihai, O.S., 2008. Mitochondrial fusion, ﬁssion and autophagy
as a quality control axis: the bioenergetic view. Biochim. Biophys. Acta 1777,
1092–1097.
Ulrich, H.D., 2009. The SUMO system: an overview. Methods Mol. Biol. 497, 3–16.
Verger, A., Perdomo, J., Crossley, M., 2003. Modiﬁcation with SUMO. A role in tran-
scriptional regulation. EMBO Rep. 4, 137–142.
Waby, J.S., Bingle, C.D., Corfe, B.M., 2008. Post-translational control of sp-family
transcription factors. Curr. Genomics 9, 301–311.
Walden,H., Podgorski,M.S., Schulman, B.A., 2003. Insights into theubiquitin transfer
cascade from the structure of the activating enzyme for NEDD8. Nature 422,
330–334.
Walsh, C.T., Garneau-Tsodikova, S., Gatto, G.J., 2005. Protein posttranslational modi-
ﬁcations: the chemistry of proteomediversiﬁcations. Angew.Chem. Int. Ed. Engl.
44, 7342–7372.
Wang, J., Feng, X.H., Schwartz, R.J., 2004. SUMO-1 modiﬁcation activated GATA4-iﬁcation by SUMO. Toxicology (2010), doi:10.1016/j.tox.2010.07.013
dependent cardiogenic gene activity. J. Biol. Chem. 279, 49091–49098.
Wei, F., Schöler,H.R., Atchison,M.L., 2007. SumoylationofOct4 enhances its stability,
DNA binding, and transactivation. J. Biol. Chem. 282, 21551–21560.
Zunino, R., Schauss, A., Rippstein, P., Navarro, M.A., McBride, H.M., 2007. The SUMO
protease SENP5 is required tomaintainmitochondrialmorphologyand function.
J. Cell Sci. 120, 1178–1188.
